Target intelligence / Profile preview

Tau protein fibril (aggregated form) (None universally accepted)

Target
None universally accepted
Molecular classification
Protein aggregate (amyloid fibril type), Other (not a classical receptor, enzyme, transporter or ion channel)
01

Overview

Tau protein fibrils are insoluble, β-sheet-rich structures formed from the aggregation of intrinsically disordered tau protein, particularly in its hyperphosphorylated state. These aggregates disrupt normal neuronal function and structure, leading to neurotoxicity and cell death in Alzheimer's disease and related disorders. In healthy brains, tau maintains microtubule stability, but during disease, abnormal post-translational modifications, truncation, and environmental co-factors (like polyanions) drive tau to assemble into filaments and tangles. Aggregated tau exhibits prion-like behavior, propagating pathogenic conformations from cell to cell. Drug discovery efforts focus on preventing tau misfolding, interfering with aggregate formation, or promoting selective clearance of pathological assemblies[1][2][3][4][7][8][9].

Other names
Tau fibrilAggregated tau proteinAmyloid tau fibrilNeurofibrillary tangle (for higher-order tissue structures)
02

Mechanism of action

Direct binding to fibril and destabilization/disaggregation. Disruption of β-sheet stacking by charge repulsion and void formation (EGCG). Inhibition of aggregation by binding to repeat/hexapeptide motifs in tau.

03

Biological functions

Microtubule stabilization (native soluble tau)In aggregated form, loss of physiological functionInduction of synaptic dysfunctionCell death (apoptosis/necrosis due to neurotoxicity)Disruption of mitochondrial and lysosomal function
04

Disease associations

Neurodegenerative disease (notably Alzheimer's disease, frontotemporal dementia, Pick’s disease, progressive supranuclear palsy, chronic traumatic encephalopathy)
05

Safety considerations

Targeting protein aggregates can risk interfering with normal tau function (microtubule assembly)Clearance of tau aggregates may provoke neuroinflammation or toxicity from soluble intermediatesAmyloid-targeting strategies risk off-target effects and poor CNS penetrance
06

Interacting drugs

Epigallocatechin gallate (EGCG, from green tea)

2 more in the full profile.

07

Biomarkers

CSF tau protein (total tau, phosphorylated tau, e.g. P-tau181, P-tau231)Tau PET imaging ligands ([^18^F]AV1451/T807, [^11^C]PBB3, [^18^F]THK5351, [^18^F]THK5117)Plasma tau (less specific, but used for screening)

Beyond the preview

Go deeper on Tau protein fibril (aggregated form) (None universally accepted).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tau protein fibril (aggregated form) (None universally accepted).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call